Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Theriva Biologics ( (TOVX) ) is now available.
On October 8, 2025, Theriva Biologics presented preclinical data for VCN-12, an enhanced oncolytic adenovirus, at the European Society of Gene & Cell Therapy Congress. The data demonstrated VCN-12’s superior tumor cell killing and immune response stimulation compared to its predecessor VCN-01, showing promise in reducing tumor growth and inducing long-lasting immunity in animal models. Further studies are planned to expand on these findings, potentially impacting the company’s position in cancer treatment innovation.
The most recent analyst rating on (TOVX) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Theriva Biologics faces substantial financial difficulties with no revenue and growing losses, which is a major concern. While technical indicators show some short-term positive momentum, the long-term trend remains negative. The lack of profitability impacts valuation. However, the recent positive clinical trial results provide a potential future catalyst that could improve the company’s prospects.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Theriva Biologics, Inc. operates in the biotechnology industry, focusing on the development of oncolytic adenoviruses for cancer treatment. The company is known for its VCN-X discovery program, which aims to create advanced therapies for cancer patients.
Average Trading Volume: 695,866
Technical Sentiment Signal: Sell
Current Market Cap: $3.93M
Find detailed analytics on TOVX stock on TipRanks’ Stock Analysis page.